SEC Comment Letter 0000000000-24-013975 to Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310) (TSHA)
Taysha Gene Therapies, Inc. (TSHA) (CIK 0001806310)
Date: Dec. 18, 2024 · CIK: 0001806310 · Accession: 0000000000-24-013975
AI Filing Summary & Sentiment
File numbers found in text: 333-283801
Letter
December 18, 2024 Sean P. Nolan Chief Executive Officer Taysha Gene Therapies, Inc. 3000 Pegasus Park Drive, Suite 1430 Dallas, Texas 75247 Re:Taysha Gene Therapies, Inc. Registration Statement on Form S-3 Filed December 13, 2024 File No. 333-283801 Dear Sean P. Nolan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Madison A. Jones
Show Raw Text
December 18, 2024
Sean P. Nolan
Chief Executive Officer
Taysha Gene Therapies, Inc.
3000 Pegasus Park Drive, Suite 1430
Dallas, Texas 75247
Re:Taysha Gene Therapies, Inc.
Registration Statement on Form S-3
Filed December 13, 2024
File No. 333-283801
Dear Sean P. Nolan:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Madison A. Jones